Chronic pruritus: From pathophysiology to drug design

Martins, Márcia; Almeida, Isaobel F.; Cruz, Maria Teresa; Sousa, Emília

doi:10.1016/j.bcp.2023.115568

Cited by 3 publications

(2 citation statements)

References 247 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Itch is generally classified as acute (<6 weeks) or chronic, lasting longer than six weeks. Chronic itch is a common symptom of multiple skin diseases, namely allergic contact dermatitis (ACD), AD, psoriasis, chronic urticaria, xerosis cutis, and other skin diseases such as prurigo nodularis, epidermolysis bullosa, lichen planus, actinic prurigo, morgellons disease, and aquagenic pruritus [8][9][10][11]. Chronic itch is divided into four categories: dermatological, systemic, neurological, and psychogenic [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Targeting Transient Receptor Potential (TRP) Channels, Mas-Related G-Protein-Coupled Receptors (Mrgprs), and Protease-Activated Receptors (PARs) to Relieve Itch

Tsagareli,

Follansbee,

Iodi Carstens

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

Itch (pruritus) is a sensation in the skin that provokes the desire to scratch. The sensation of itch is mediated through a subclass of primary afferent sensory neurons, termed pruriceptors, which express molecular receptors that are activated by itch-evoking ligands. Also expressed in pruriceptors are several types of Transient Receptor Potential (TRP) channels. TRP channels are a diverse class of cation channels that are responsive to various somatosensory stimuli like touch, pain, itch, and temperature. In pruriceptors, TRP channels can be activated through intracellular signaling cascades initiated by pruritogen receptors and underly neuronal activation. In this review, we discuss the role of TRP channels TRPA1, TRPV1, TRPV2, TRPV3, TRPV4, TRPM8, and TRPC3/4 in acute and chronic pruritus. Since these channels often mediate itch in association with pruritogen receptors, we also discuss Mas-related G-protein-coupled receptors (Mrgprs) and protease-activated receptors (PARs). Additionally, we cover the exciting therapeutic targets amongst the TRP family, as well as Mrgprs and PARs for the treatment of pruritus.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Most types of chronic itch are resistant to antihistamines, so there is a pressing need to develop novel drugs other than antihistamines to treat itch. However, to date the management and treatment of itch remains challenging because therapeutic options have frequently been reported as inadequate [9,[14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Targeting Transient Receptor Potential (TRP) Channels, Mas-Related G-Protein-Coupled Receptors (Mrgprs), and Protease-Activated Receptors (PARs) to Relieve Itch

Tsagareli,

Follansbee,

Iodi Carstens

et al. 2023

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

Neutrophil-derived oxidative stress contributes to skin inflammation and scratching in a mouse model of allergic contact dermatitis via triggering pro-inflammatory cytokine and pruritogen production in skin

Yang,

Pan,

Liu

et al. 2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study

Hartzell,

Szabova,

Collins

et al. 2024

Pediatric Dermatology

View full text Add to dashboard Cite

IntroductionAt a single‐center pediatric hospital, the neurokinin‐1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).MethodsThirty‐seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.Results58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age‐related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.ConclusionsAprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.

show abstract

Chronic pruritus: From pathophysiology to drug design

Cited by 3 publications

References 247 publications

Targeting Transient Receptor Potential (TRP) Channels, Mas-Related G-Protein-Coupled Receptors (Mrgprs), and Protease-Activated Receptors (PARs) to Relieve Itch

Targeting Transient Receptor Potential (TRP) Channels, Mas-Related G-Protein-Coupled Receptors (Mrgprs), and Protease-Activated Receptors (PARs) to Relieve Itch

Neutrophil-derived oxidative stress contributes to skin inflammation and scratching in a mouse model of allergic contact dermatitis via triggering pro-inflammatory cytokine and pruritogen production in skin

Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study

Contact Info

Product

Resources

About